Dyslipidemia associated with subclinical hypothyroidism in Eastern Nepal

Rajaram Yadav¹, Ashwini Kumar Nepal¹, Vishwajeet Rohil², Basanta Gelal¹, Rajendra Kumar Chaudhari¹, Punam Jha¹, Shreejana Shrestha¹, Madhab Lamsal¹, Nirmal Baral¹

¹Department of Biochemistry, B.P. Koirala Institute of Health Sciences, Dharan, Nepal, ²Department of Clinical Biochemistry, Vallabhbhai Patel Chest Institute, University of Delhi, Dehli, India

ABSTRACT

Objectives: The present study was conducted aiming to investigate lipid profile in patients with subclinical hypothyroidism as compared to age and sex matched controls. Methods: The study population consisted of total 80 subjects; 40 patients (cases) and 40 controls. Serum free tri-iodothyronine (fT₃) and free thyroxine (fT₄) were estimated by microplate competitive enzyme immunoassay, and thyroid stimulating hormone (TSH) measured by sandwich enzyme immunoassay. Lipid profile tests: Total Cholesterol, triglycerides, high density lipoprotein (HDL) cholesterol were estimated by enzymatic methods and low density lipoprotein cholesterol (LDL) was calculated by Friedewald’s formula. Results: Significant differences were observed between lipid parameters in case Vs controls: total cholesterol (4.9±1.1 Vs 4.3±1.0 mmol/L, P=0.03), triglycerides (1.9±0.7 Vs 1.6±0.6 mmol/L, P=0.02) and LDL cholesterol levels (3.5±1.1 Vs 2.9±0.9 mmol/L, P=0.02). In case Vs controls no significant differences were observed between HDL Cholesterol (1.1±0.2 Vs 1.1±0.7 mmol/L, P=0.07), VLDL (0.9±0.4 Vs 0.8±0.3 mmol/L, P=0.1) and Cholesterol/ HDL ratio (4.48±1.40 Vs 4.06±0.89, P=0.118). Elevated TSH level were found in cases Vs controls (12.42±7.08 Vs 2.69±0.20 mIU/L, P=0.01) which was statistically significant. The subjects on control group were euthyroid, however increased fT₃ (3.9±0.8Vs 4.6±0.8 pmol/L, P=<0.01) and fT₄ (17.1±3.9Vs 21.2±.3.7 pmol/L, P=<0.01) values were observed in controls than cases, which was statistically significant. Conclusion: The results of the present study suggest that cases of subclinical hypothyroidism are at risk of dyslipidemia as compared to controls. Large population based studies are needed to generalize these findings and establish the therapeutic guidelines for implementing lipid lowering agents in subclinical hypothyroidism.

Key words: Lipid profile, Thyroid hormones, Subclinical hypothyroidism

INTRODUCTION

Iodine deficiency, thyroid dysfunction, along with prevalence of goiter, is a major public health problem in Nepal.¹² Nepal lies in an area of endemic iodine deficiency, with about 30% prevalence of thyroid dysfunction from previous studies.⁴-⁶ Hypothyroidism is defined as a deficiency of thyroid activity. It results from reduced secretion of both thyroxine (T₄) and tri-iodothyronine (T₃). Biochemically decrease in T₄ and T₃ concentrations leads to increased secretion of thyroid stimulating hormone (TSH) from the pituitary gland and an amplified increase in serum TSH.⁷ Hypothyroidism results from inadequate production of thyroid hormones, and is classified as overt or subclinical depending on the degree of clinical severity and the extent of abnormalities in thyroid hormone levels.⁸ Subclinical hypothyroidism (SH) is a hypothyroid condition usually asymptomatic, in which free T₄ and T₃ levels are within reference range and TSH level is above the reference range, or if a thyrotropin releasing hormone (TRH) test is conducted, there’s a greater than normal elevation in TSH response.⁹ Thyroid hormones play important role in regulation of energy homeostasis, glucose and lipid metabolism and regulate some key enzymes of lipoprotein transport.¹⁰-¹² Lipid abnormalities are reported to be more common in patients with overt hypothyroidism and are

Address for Correspondence:
Dr. Vishwajeet Rohil, Department of Clinical Biochemistry, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi – 110 007, India.
E-mail: vishrohil@gmail.com; Phone: +91-9810224000.
thought to contribute to the disproportionate increase in cardiovascular risk in those persons. SH is found to be associated with lipid disorders, characterized by normal or slightly elevated total cholesterol, increased LDL and lower HDL. SH is also associated with endothelium dysfunction, aortic atherosclerosis and myocardial infarction.13-15
Prevalence of SH in eastern region of Nepal, was 20.42% and increased Total Cholesterol was associated with increasing age in hypothyroid and sub-clinical hypothyroid subjects in our previous study.16,17 The present study was conducted aiming to investigate lipid profile in patients with subclinical hypothyroidism as compared to age and sex matched controls.

**MATERIALS AND METHODS**

The present study was conducted in Immunoassay Laboratory, Department of Biochemistry, B.P. Koirala Institute of Health Sciences (BPKIHS), Dharan, Nepal. The study population comprised of, total 40 cases having sub-clinical hypothyroidism and 40 age and sex matched healthy (euthyroid) controls.

**Inclusion criteria**

For Cases: All newly diagnosed cases of subclinical hypothyroid patients (n=40) visiting Immunoassay Laboratory, B.P. Koirala Institute of Health Sciences within the study period were included in this study. Patients with normal fT₃ (2.2-6.5 pmol/L), fT₄ (10.4-28.4 pmol/L) and TSH level above 6.2 mIU/L (0.3-6.2 mIU/L) were considered having subclinical hypothyroidism.

For Controls: Age and sex matched normal euthyroid subjects (N=40) were included.

**Exclusion criteria**

The patients who were diagnosed as hyperthyroid and hypothyroid were not included in this study. Patients on any kinds of medications, hormonal preparations and oral contraceptives/lipid lowering agents were excluded, as well as patients with diabetes mellitus, renal failure, hypertension, any other chronic illness were also excluded.

**Thyroid hormones and Lipid Profile Assay**

After 12-14 hours fasting three milliter blood sample was collected by venipuncture in all subjects in a plain vial. On the same day of collection, serum was separated by centrifugation (REMI Research Centrifuge Model R-23, India) at 2500 rpm for 15 minutes at room temperature and stored at -20°C until analysis. Serum fT₃ and fT₄ were estimated by competitive Enzyme Linked Immunosorbtent Assay (ELISA) and TSH was estimated by sandwich ELISA (Human Diagnostic, Germany). All the parameters of lipid profile, total cholesterol, triglycerides (TG), high density lipoprotein (HDL) were assayed using enzymatic methods (Human Diagnostic, Germany). Very low density lipoprotein (VLDL) and low density lipoprotein (LDL) cholesterol were calculated using Friedewald’s formula.21 Reference ranges for lipid parameters were: Total cholesterol (<5.2 mmol/L), Triglycerides: (0.7–1.9 mmol/L), LDL cholesterol (<3.4 mmol/L), HDL cholesterol (>1.1 mmol/L), VLDL cholesterol (0.1-0.9 mmol/L), Total cholesterol/HDL (<5).

Ethical clearance was approved as per the guidelines of Institutional Ethical Review Board (IERB), B.P. Koirala Institute of Health Sciences, Dharan, Nepal.

**Statistical analysis**

Data were entered into Microsoft Excel 2007, and statistical analysis was performed using the statistical package for social sciences (SPSS) version 20 (SPSS Inc. Chicago, USA). Normality of the data was tested using Shapiro-Wilk test. Data were presented as Mean±SD. Student ‘t’ test was used to compare the mean values between cases and controls. Pearson’s correlation test was applied to compare correlation between TSH & lipid parameters. P value of less than 0.05 was considered as statistically significant at 95% confidence intervals.

**RESULTS**

The mean age of patients (37.42±13.9) was comparable to that of control’s age (35.10 ± 10.10) years (P=0.3). There were 35(44%) female & 5(6%) male in cases group and 36(45%) female & 4(5%) male in control group. Significant differences were observed between lipid parameters in case Vs controls: total cholesterol (4.9±1.1 Vs 4.3±1.0 mmol/L, P=0.03), triglycerides (1.9±0.7 Vs 1.6±0.6 mmol/L, P=0.02) and LDL cholesterol levels (3.5±1.1 Vs 2.9±0.9 mmol/L, P=0.02). In case Vs controls no significant differences were observed between HDL Cholesterol (1.1±0.2 Vs 1.1±0.7 mmol/L, P=0.07), VLDL (0.9±0.4 Vs 0.8±0.3 mmol/L, P=0.1) and Cholesterol/HDL ratio (4.4±1.4 Vs 4.06±0.8, P=0.1). Elevated TSH level was found in cases Vs controls (12.4±7.0 Vs 2.6±0.2 mIU/L, P=0.01) which was statistically significant. The subjects on control group were euthyroid, however increased fT₃ (3.9±0.8 Vs 4.6±0.8 pmol/L, P=0.01) and fT₄ (17.1±3.9 Vs 21.2±3.7 pmol/L, P=0.01) were observed in controls than cases, which was statistically significant (Table 1). Total cholesterol, triglycerides and VLDL levels were positively correlated with serum TSH but it was not statistically significant (r=0.09, P=0.4), (r=0.1, P=0.2), (r=0.04, P=0.6) respectively. LDL cholesterol showed highly significant positive correlation (r=0.2, P=0.04) with serum TSH level. Whereas, HDL cholesterol showed significant negative correlation (r =-0.2, P=0.02) with TSH (Table 2).
that TG and LDL cholesterol are significantly increased in cases and a highly significant positive correlation was also observed between LDL cholesterol and TSH levels. Which is in concordance with previous studies, due to the fact that, serum cholesterol levels are increased in hypothyroidism, due to effects of thyroid hormones in LDL synthesis and degradation.\textsuperscript{28} HDL cholesterol and VLDL did not differ significantly as compared to controls. No significant relationship was found between cholesterol, HDL, or LDL levels and SH. Some studies have shown an increase in HDL cholesterol levels in SH whereas others show either no change or decrease.\textsuperscript{22, 24} Plasma HDL concentration is reported normal or elevated in severe hypothyroidism, because thyroid hormones participate in regulation of Cholesterol Ester Transfer Protein (CETP) and Hepatic Lipase (HL). It has also been shown in some studies that correction of hypothyroidism with the thyroid hormone levothyroxine reverses the lipid abnormalities.\textsuperscript{9, 29} On the basis of outcome of the present study, it is proposed that the measurement of serum TSH be included in the screening of patients with dyslipidemia. Patients diagnosed with SH may be followed up to see whether the patient gets converted to overt disease state. The effect of treatment of thyroid disorders on the restoration of lipid metabolism has immense potential clinical implication in developing therapeutic guidelines and needing further elaborative studies. The alterations of lipids parameters can lead to development of atherosclerosis, which has serious consequences like development of coronary artery disease, stroke, etc.\textsuperscript{29, 30} In the present study, total cholesterol, triglycerides and LDL cholesterol levels were significantly higher in cases as compared to controls though the HDL and VLDL levels did not differ significantly. The results of the present study suggest that cases of SH are at risk of dyslipidemia as compared to controls. Large population based studies are needed to generalize these findings and establish the therapeutic guidelines for implementing lipid lowering agents in subclinical hypothyroidism, also it is essential to consider the associated genetic factors related to SH and dyslipidemia in further studies.

### DISCUSSION

The Wickham Survey\textsuperscript{8} and the Colorado study\textsuperscript{11} have shown prevalence of SH in 7.5% males and 3.1% females in general population. In these surveys, the mean total cholesterol and LDL cholesterol progressively increased with increasing levels of serum TSH and hypercholesterolemia was associated with mild elevations of TSH levels. In some studies from India: i) Singh K et al, 2011 showed significant increase in triglycerides and VLDL cholesterol and nominal increases in serum cholesterol, LDL and HDL levels in SH patients as compared to controls,\textsuperscript{22} ii) Bandyopadhyay et al, 2006 reported significant elevations in SH patients as compared to controls, and increased levels of serum lipoprotein (a) in age above 20 years and total cholesterol, triglyceride and LDL in age groups of 40-50 years,\textsuperscript{23} iii) Asranna A et al, 2012 showed increased level of total cholesterol and LDL levels and no significant elevations in VLDL and triglyceride levels and HDL cholesterol was lower in SH patients than controls but not statistically significant.\textsuperscript{24} In few other studies, total cholesterol and LDL Cholesterol were found to be elevated in cases as compared with controls.\textsuperscript{25-27} Our findings are in agreement with these studies, showing that dyslipidemia is significantly associated with subclinical hypothyroidism. In the present study, total cholesterol level was found to be significantly higher in cases than controls. It was observed

### Table 1: Biochemical parameters in cases and controls

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Cases</th>
<th>Controls</th>
<th>P value (total)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cholesterol (mmol/L)</td>
<td>Male: 3.4±0.5</td>
<td>Female: 4.9±1.0</td>
<td>0.04</td>
</tr>
<tr>
<td></td>
<td>4.9±1.1</td>
<td></td>
<td>0.09</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>Male: 1.4±0.4</td>
<td>Female: 1.9±0.7</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>1.9±0.7</td>
<td></td>
<td>0.57</td>
</tr>
<tr>
<td>LDL Cholesterol (mmol/L)</td>
<td>Male: 2.2±0.6</td>
<td>Female: 3.6±0.9</td>
<td>0.008</td>
</tr>
<tr>
<td></td>
<td>3.5±1.1</td>
<td></td>
<td>0.31</td>
</tr>
<tr>
<td>HDL Cholesterol (mmol/L)</td>
<td>Male: 0.9±0.1</td>
<td>Female: 1.1±0.2</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td>1.1±0.2</td>
<td></td>
<td>0.13</td>
</tr>
<tr>
<td>VLDL (mmol/L)</td>
<td>Male: 0.7±0.2</td>
<td>Female: 0.9±0.4</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td>0.9±0.4</td>
<td></td>
<td>0.21</td>
</tr>
<tr>
<td>Cholesterol/HDL</td>
<td>Male: 3.3±0.8</td>
<td>Female: 4.7±1.5</td>
<td>0.06</td>
</tr>
<tr>
<td></td>
<td>4.5±1.5</td>
<td></td>
<td>0.25</td>
</tr>
<tr>
<td>TSH (mIU/L)</td>
<td>Male: 12.4±7.9</td>
<td>Female: 12.4±7.1</td>
<td>0.9</td>
</tr>
<tr>
<td></td>
<td>12.5±7.1</td>
<td></td>
<td>0.38</td>
</tr>
<tr>
<td>fT (pmol/L)</td>
<td>Male: 3.6±0.8</td>
<td>Female: 3.9±0.4</td>
<td>0.04</td>
</tr>
<tr>
<td></td>
<td>3.9±0.8</td>
<td></td>
<td>0.35</td>
</tr>
<tr>
<td>fT' (pmol/L)</td>
<td>Male: 18.5±4.1</td>
<td>Female: 16.9±3.9</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td>17.1±3.9</td>
<td></td>
<td>0.26</td>
</tr>
</tbody>
</table>

*Student 't' test was applied for male/female, cases/controls and total at 95% confidence intervals

### Table 2: Correlation between TSH and lipid profile parameters in case Vs Control

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Case</th>
<th>Control</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol</td>
<td>-0.2</td>
<td>0.2</td>
<td>0.09</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>-0.08</td>
<td>0.7</td>
<td>0.24</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>-0.17</td>
<td>0.3</td>
<td>0.24</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>-0.2</td>
<td>0.2</td>
<td>0.06</td>
</tr>
<tr>
<td>VLDL</td>
<td>0.14</td>
<td>0.4</td>
<td>0.02</td>
</tr>
</tbody>
</table>

Pearson’s correlation test was applied between TSH and lipid profile parameters in cases, controls and total. Significant correlations are represented by asterisk (*).
ACKNOWLEDGEMENT

We would like to cordially thank Department of Biochemistry, B.P. Koirala Institute of Health Sciences for supporting this study.

REFERENCES


9. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004;291(2):228-238.


Authors Contribution:
RY – designed the study, performed the laboratory tests and drafted the manuscript; AKN – analysed the data and drafted the manuscript; VR – designed the experiments and reviewed the manuscript; BG – contributed to the study design; RKC – contributed to the study design; PJ – contributed to the study design; SS – contributed to the study design; ML – designed the experiments and reviewed the manuscript; NB – designed the experiments and reviewed the manuscript.

Source of Support: Department of Biochemistry, B.P. Koirala Institute of Health Sciences, Dharan, Nepal, Conflict of Interest: None declared.